tbuckley/cabot-search huggingface dataset:
MILITARY MEDICINE OF THE DAY.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Les assistants d'endoscopie influencent-ils la qualité de la coloscopie
Journal: Endoscopy (2018)

Au cours des dernières années, les indicateurs de qualité de la coloscopie ont fait l’objet de beaucoup d’attention, notamment la performance individuelle des endoscopistes. Moins d'attention a été consacrée aux assistants, ou aide, ou infirmiers d'endoscopie. Selon le pays, l'assistant peut jouer un rôle important dans les activités suivantes: informer et préparer le patient pour la coloscopie; guider le patient pendant la procédure; perfuser le patient; administrer une sédation; réaliser une compression abdominale pendant l'examen et détecter la pathologie tout en regardant l'écran.
396PD IL-2 synergizes with PD-1/PD-L1 blockade via CD28/CHK1 pathway to enhance CD81 T cell responses in lung squamous cell carcinoma
Authors: S-M. Huang, S-P. Wu, R-Q. Liao, Z-Y. Dong, H. Tu, Z. Xie, J. Su, J-J. Yang, X. Zhang, Y-L. Wu
Journal: Annals of Oncology (2016)
TOPICAL GLYCERYL TRINITRATE TREATMENT OF CHRONIC PATELLAR TENDINOPATHY: A RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED CLINICAL TRIAL
Authors: J Zwerver, M Steunebrink, R Brandsema, P Groenenboom, I van den Akker-Scheek, A Weir
Journal: British Journal of Sports Medicine (2013)

Introduction From previous research on tendinopathy of the Achilles tendon, wrist extensors and the supraspinatus, it is known that topical glyceryl trinitrate (GTN) has a healing effect. To our knowledge, no studies have been published on the application of GTN in patients with PT. The aim of this study was to assess if continuous topical GTN treatment improved outcome in patients with chronic PT compared to placebo patches, both combined with heavy load eccentric training. Methods A randomised double blind, placebo-controlled clinical trial was done, comparing a 12 week programme of using a GTN patch or placebo patch in combination with eccentric squats on a decline board. Measurements were performed at baseline, 6, 12 and 24 weeks. Primary outcome measure was the VISA-P questionnaire. Secondary outcome measures were patient satisfaction and pain scores during sports. Generalised Estimated Equation was used to analyse the treatment, time and treatment x time effect. Analyses were performed following the intention-to-treat principle. Results VISA-P scores for both groups improved over the study period to 75.0±16.2 and 80.7±22.1 at 24 weeks. Results showed a significant effect for time (p&lt;0.01) but no effect for treatment x time (p=0.80). Mean VAS pain scores during sports for both groups increased over the study period to 6.6±3.0 and 7.8±3.1. Results showed a significant effect for time (p&lt;0.01) but no effect for treatment x time (p=0.38). Patient satisfaction showed no difference between the GTN and the placebo group (p=0.25) after 24 weeks, but did show a significant difference over time (p=0.01). Three patients in the GTN group reported some rash. Discussion Continuous topical GTN treatment in addition to an eccentric exercise programme does not improve clinical outcome compared to placebo patches and an eccentric exercise programme in patients with chronic patellar tendinopathy.
Requirement of TH1 like liver lymphocytes for endotoxin-induced liver apoptosis . Toneyama Inst. Osaka City Univ., Osaka, and *Dept. Immunol. and �3rd Dept. of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan
Journal: Hepatology (1995)

The expression of c-myb mRNA and protein was analyzed in fresh leukemic cells by Northern-blot analyses and by immunofluorescent staining using monoclonal c-myb specific antibodies. Staining of the cells was evaluated by flow cytometry. The results demonstrate c-myb mRNA expression predominantly in acute lymphocytic leukemia (ALL, 4/4 cases), acute myeloic leukemia (AML, 1717) and chronic myeloic leukemia (CML, 1212) but rarely in chronic lymphocytic leukemia (CLL, 117). Immunofluorescent analyses revealed expression of c-myb protein in the nucleus of ALL (57) and AML (99) with a good correlation of c-myb-positive cells and with the number of proliferating (Ki67-positive) blast cells.
HLA-Cw6和银屑病
Authors: L. Chen, T.-F. Tsai
Journal: British Journal of Dermatology (2018)

Summary 银屑病是一种皮肤病,除了其他的症状之外,可能会导致皮肤出现红色鳞片状斑块。这是一种由若干种不同因素共同作用而导致的复杂疾病,包括环境因素和基因因素。由于这些变量,银屑病对患者的影响也不尽相同,包括症状、受影响的身体部位,以及治疗的作用。同一基因的不同版本称为等位基因,而一些等位基因则会使某个人更容易患上某些疾病或症状。银屑病敏感性等位基因被认为在这种疾病的发展中起着重要的作用,尤其是被称为HLA-Cw6的等位基因,它与早发性银屑病等特征和某种叫做斑点病变的皮肤斑块(病变)类型有关。这篇由国立台湾大学医学院附设医院发表的文章回顾并总结了来自一系列针对HLA-Cw6和银屑病的研究的关键发现。HLA-Cw6,但高加索人的频率普遍更高。这种等位基因与类型I早发性银屑病有关。具有HLA-Cw6等位基因的患者(HLA-Cw6阳性患者)中通常会出现压力、肥胖和称为链球菌咽炎的感染症状。一些研究发现,HLA-Cw6与一种称为滴状银屑病的银屑病有关。此外,携带这种等位基因的患者更有可能在手臂、双腿和躯体上出现病变。研究还表明,与未携带这种等位基因的患者相比,HLA-Cw6阳性患者接受某些治疗的成功率更高。所有这些发现最终都有助于预知和计划不同患者的银屑病将会如何发展和治疗,尽管还需要进行更多的研究。
LUME-Colon 1: A double-blind, randomized phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer (CRC) refractory to standard therapies.
Authors: Heinz-Josef Lenz, Josep Tabernero, Takayuki Yoshino, Zohra Oum'Hamed, Soetkin Vlassak, Mouna Sassi, Eric Van Cutsem
Journal: Journal of Clinical Oncology (2015)

TPS3625 Background: Clinical studies with anti-VEGF agents, such as regorafenib (R), demonstrate that angiogenesis is critical to CRC tumor growth and metastasis. R has provided proof of principle in patients (pts) with refractory CRC, but is associated with a specific safety profile; there is a need for effective alternative treatments with different safety profiles. Nintedanib (N) is a triple angiokinase inhibitor of VEGF, PDGF and FGF signaling. N is approved in the European Union for the treatment of pts with advanced adenocarcinoma NSCLC after 1st-line chemotherapy and has shown clinical benefit in trials in several tumor types. In a phase I study of N in CRC, a clinically relevant anti-angiogenic effect was observed in 67% of pts. These findings and a manageable safety profile provide a rationale to examine N in refractory CRC. The objective of this study (NCT02149108; 1199.52) is to evaluate the efficacy and safety of N in pts with refractory CRC after failure with standard chemotherapy and biologic agents. Methods: 764 pts worldwide (including 10 US sites) – age ≥ 18 years, ECOG-PS 0–1, and histologically/cytologically confirmed CRC adenocarcinoma not amenable to surgery and/or radiotherapy – will be randomized 1:1 to receive either N (200 mg bid) + BSC or placebo (bid) + BSC in 21-day courses until disease progression or undue toxicity. The study is powered to distinguish a clinically meaningful effect in the co-primary endpoints PFS and OS. Secondary endpoints are objective tumor response and disease control. Pts will be stratified at randomization based on previous R treatment, time from onset of metastatic disease to randomization and region. PFS and OS will be evaluated by the log-rank test to determine the effect of N independently at the two-sided alpha level of 0.05. Other assessments include frequency and severity of adverse events and changes in laboratory parameters to measure safety; health-related quality of life; and biomarker analyses focusing on exploring predictive biomarkers and drug resistance mechanisms. As of Jan 7, 2015, 180 pts were randomized and recruitment is ongoing. Results are expected in 2016. Clinical trial information: NCT02149108.
Carotid Artery Stenosis—Hemodynamic Significance and Clinical Course
Authors: Ronald W. Busuttil
Journal: JAMA (1981)

Two hundred fifteen patients with a history of either stroke, transient ischemic attack (TIA), or asymptomatic carotid bruit underwent noninvasive carotid artery testing using oculopneumoplethysmography. Of patients with hemodynamically significant stenosis, 51 (40.8%) underwent endarterectomy, and 74 (59.2%) were treated nonoperatively. The incidence of stroke in the nonoperated group was 12/74 (16.2%) compared with only 1/51 (1.9%) in the operated group. Similarly, recurrent TIA occurred in 29/74 (39.2%) of the nonoperated group vs 9/51 (17.6%) of the operated. In nonhemodynamically significant carotid stenosis, the risk of cerebrovascular death and stroke was exceedingly low: 2/90 (2.2%). Patients with hemodynamically significant stenosis treated nonoperatively have a greater risk of cerebrovascular death, stroke, and TIA than patients treated with carotid endarterectomy. (<i>JAMA</i>1981;245:1438-1441)
Cutaneous metastases from carcinoma of the colon
Authors: J. A. Gottlieb
Journal: JAMA (1970)

<h3>To the Editor.—</h3> Cutaneous metastases from carcinoma of the colon are relatively uncommon, having been reported in less than 4% of patients with colonic cancer coming to autopsy.<sup>1,2</sup>When this type of metastasis does appear, however, it may be the first evidence of tumor spread,<sup>3,4</sup>and thus warn the clinician. Since the gross appearance of these metastases is not distinctive,<sup>3</sup>early biopsy is most important. We have recently treated two patients with adenocarcinoma of the colon in whom the first manifestation of tumor spread was the appearance of rather striking skin metastases. In both cases, delay between the appearance of the skin lesions and the recognition (by biopsy) of their true nature lost the opportunity to institute further therapy while the tumor mass was still small. The first patient had extensive metastases to the hands 4 1/2 years after the removal of the primary tumor, while the
Inhalation Pharmacokinetics of 1,3-Butadiene and 1,2-Epoxybutene-3 in Rats and Mice
Authors: Reinhold J. Laib, Johannes G. Filser, Reinhard Kreiling, Rao R. Vangala, H. M. Bolt
Journal: Environmental Health Perspectives (1990)

Studies were conducted on inhalation pharmacokinetics of 1,3-butadiene and of its primary reactive metabolic intermediate 1,2-epoxybutene-3 in rats (Sprague-Dawley) and mice (B6C3F1). Investigations of inhalation pharmacokinetics of 1,3-butadiene revealed saturation kinetics of 1,3-butadiene metabolism in both species. For rats and mice linear pharmacokinetics apply at exposure concentrations below 1000 ppm 1,3-butadiene; saturation of 1,3-butadiene metabolism is observed at atmospheric concentrations of about 2000 ppm. The estimated maximal metabolic elimination rates were 400 mumole/hr/kg for mice and 200 mumole/hr/kg for rats. This shows that 1,3-butadiene is metabolized by mice at about twice the rate of rats. Investigations of inhalation pharmacokinetics of 1,2-epoxybutene-3 revealed major differences in metabolism of this compound between both species. No indication of saturation kinetics of 1,2-epoxybutene-3 metabolism could be observed in rats up to exposure concentrations of 5000 ppm, whereas in mice the saturation of epoxybutene metabolism became apparent at atmospheric concentrations of about 500 ppm. The estimated maximal metabolic rate for 1,2-epoxybutene-3 was 350 mumole/hr/kg in mice and greater than 2600 mumole/hr/kg in rats. When the animals are exposed to high concentrations of 1,3-butadiene, 1,2-epoxybutene-3 is exhaled by rats and mice. For rats 1,2-epoxybutene-3 concentration in the gas phase of the system reaches a plateau at about 4 ppm. For mice, 1,2-epoxybutene-3 concentration increases with exposure time until, at about 10 ppm, signs of acute toxicity are observed. Under these conditions hepatic nonprotein sulfhydryl compounds are virtually depleted in mice but not in rats.(ABSTRACT TRUNCATED AT 250 WORDS)
Multiple myeloma: A patient with unusual features including intracranial and meningeal involvement, testicular involvement, organomegaly, and plasma cell leukemia
Authors: Nazim Turhal, M. Deirdre Henehan, Karen L. Kaplan
Journal: American Journal of Hematology (1998)

A 27-year-old Chinese male presented with multiple myeloma. Over his 18-month course he manifested a number of unusual features of his disease including his young age, marked organomegaly, a testicular plasmacytoma, multiple intracranial extraskeletal plasmacytomas and meningeal involvement, and peripheral blood plasmacytosis. The case is described and recent literature on these rare manifestations is reviewed. Am. J. Hematol. 57:51–56, 1998. © 1998 Wiley-Liss, Inc.
Court orders California governor to restore antismoking media campaign funding
Authors: A. A. Skolnick
Journal: JAMA (1992)

A CALIFORNIA Superior Court judge has ordered Governor Pete Wilson and Molly J. Coye, MD, MPH, director of the Department of Health Services, to restore the funding they recently slashed from California's widely acclaimed antismoking media campaign. In his verbal decision on April 24, Sacramento Superior Court Judge James Ford told Coye that neither she nor the governor has the authority to withhold $16 million mandated by law for antismoking television and print advertising. California's deputy attorney general, Eugene Hill, who argued the case for the governor and the Department of Health Services, says they must wait to see the judge's written ruling before deciding whether to appeal the decision. The lawsuit, which was brought by the American Lung Association of California, is the latest round in what is being described as an increasingly ugly political fight over cigarette tax revenues earmarked for antitobacco programs by California's Proposition 99. (See
THE SANITY OF PRENDERGAST.
Journal: JAMA (1894)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effect of chocolate on acne vulgaris
Authors: J. E. Fulton
Journal: JAMA (1969)

To test the widespread idea that chocolate is harmful in instances of acne vulgaris, 65 subjects with moderate acne ate either a bar containing ten times the amount of chocolate in a typical bar, or an identical-appearing bar which contained no chocolate. Counting of all the lesions on one side of the face before and after each ingestion period indicated no difference between the bars. Five normal subjects ingested two enriched chocolate bars daily for one month; this represented a daily addition of the diet of 1,200 calories, of which about half was vegetable fat. This excessive intake of chocolate and fat did not alter the composition or output of sebum. A review of studies purporting to show that diets high in carbohydrate or fat stimulate sebaceous secretion and adversely affect acne vulgaris indicates that these claims are unproved.
International Union of Pharmacology. LIII. Nomenclature and Molecular Relationships of Voltage-Gated Potassium Channels
Authors: George A. Gutman, K. George Chandy, Stephan Grissmer, Michel Lazdunski, David Mckinnon, Luis A. Pardo, Gail A. Robertson, Bernardo Rudy, Michael C. Sanguinetti, Walter Stühmer, Xiaoliang Wang
Journal: Pharmacological Reviews (2005)

Potassium-selective channels are the largest and most diverse group of ion channels, represented by some 70 known loci in the mammalian genome. The first cloned potassium channel gene was the Drosophila voltage-gated shaker channel, and this was rapidly followed by the identification of other
HUMAN TUBERCULOSIS AND HOUSEHOLD PETS.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Surgeon general's final target: drunk driving
Authors: C. Marwick
Journal: JAMA (1989)

ATTEMPTING TO COPE with an estimated 24 000 deaths and 534 000 injuries from alcohol-related traffic crashes, Surgeon General C. Everett Koop, MD, is calling, among other things, for a reduction in the legal limit for blood alcohol concentration to 0.04%, an increase in liquor taxes, and limits on the way that alcohol can be advertised. The recommendations result from an earlier workshop on drunken driving (<i>JAMA</i>. 1989;261:819). Koop—who has just completed his final week on the job—says the report is being sent to Congress for action. "I want Congress to provide leadership and resources to implement the recommendations," he said. Last year both houses of Congress adopted resolutions that urged the Surgeon General to declare drunk driving a national crisis and to try to bring the problem under control. Industry officials have expressed doubt that alcohol advertising will face restrictions similar to those imposed on cigarette advertisements.
Effects of Concurrent Administration of Lead, Cadmium, and Arsenic in the Rat
Authors: Kathryn R. Mahaffey, Bruce A. Fowler
Journal: Environmental Health Perspectives (1977)

Humans are exposed to a number of toxic elements in the environment; however, most experiments with laboratory animals investigate only one toxic element. To determine if concomitant exposure to lead (Pb), cadmium (Cd), and/or arsenic (As) modified the changes produced by any one metal in various parameters of toxicity, 168 male, Sprague-Dawley, young adult rats were fed nutritionally adequate diets to which had been added 0 or 200 ppm Pb as Pb acetate, or 50 ppm Cd as Cd chloride, or 50 ppm As as sodium arsenate or arsanilic acid in a factorial design for a period of 10 weeks. At these concentrations, Cd and As reduced weight gain even when differences in food intake were taken into account; administration of both Cd and As depressed weight gain more than did either metal alone. Pb did not adversely affect food consumption or weight gain. Increased numbers of red blood cells (RBCs) were observed following administration of Pb, Cd, or As; usually more cells were observed when two or three metals were administered, compared to individual metals. Despite increasing numbers of circulating RBCs, hemoglobin and hematocrit were reduced, especially with the Pb-Cd combination and the Cd-arsanilic acid combination. Specific effects of Pb on heme synthesis were observed, including increased urinary excretion of δ-aminolevulinic acid; this increase was reduced by the presence of dietary cadmium. Analyses of blood showed values for the laboratory rat within normal ranges for blood urea nitrogen, creatinine, cholesterol, calcium, albumin, total protein, and bilirubin. Uric acid was increased by Pb, with little modification by dietary Cd or As content. Serum glutamate-oxalate transaminase activity was reduced by As. Serum alkaline phosphatase was greatly reduced by either As or Cd but not Pb. Combinations of As and Cd did not further reduce the activity of this enzyme. Kidney weight and kidney weight/body weight ratios were increased by Pb alone, with no effects of Cd or As alone or as interactions. Liver weight/body weight ratios were reduced in animals fed 50 ppm dietary Cd. Kidney histology shows predominantly Pb effects, namely, intranuclear inclusion bodies and cloudy swelling. Ultrastructural evaluation of kidneys from Pb-treated animals disclosed nuclear inclusion bodies of the usual morphology and mitochondrial swelling. Concurrent administration of Cd greatly minimized Pb effects on the kidney under conditions of this experiment. Liver histology suggests an increased rate of cell turnover with either As compound, but few specific changes.
NEWSPAPER IGNORANCE AND SCIENTIFIC MEDICINE.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Universal Health Coverage: realistic and achievable?
Authors: None The Lancet Public Health
Journal: The Lancet Public Health (2019)

On Dec 12, 2012, the UN General Assembly endorsed a resolution urging countries to accelerate progress toward Universal Health Coverage (UHC). Since 2017, Dec 12 has been proclaimed as an official UN-designated day: International Universal Health Coverage Day—a day for the global movement supporting UHC to raise awareness and to call on political leaders to deliver access to health care for all.